- Global Pharma News & Resources

HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

DGAP-News: HAEMATO AG / Key word(s): Takeover/Capital Increase
15.12.2020 / 15:10
The issuer is solely responsible for the content of this announcement.

Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company's share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a capital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.01.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

With this transaction, M1 Kliniken AG is pursuing its strategy to focus the company on the beauty treatment business, which began in mid-2020, while the trading and product business will be bundled in the subsidiary HAEMATO AG. In addition the combination of the product and trading activities of M1 Aesthetics under the umbrella of HAEMATO AG, it is the long-term strategy of the M1 Kliniken Group to increase the vertical integration of its own activities. To this end, it is intended to establish a selection of high-quality treatment products (hyaluronic acid and botulinum toxin) as a "M1 private label" in the medium term and thereby strengthen the earning power, especially in the entry-level price segment.

Mr. Patrick Brenske, member of the board of HAEMATO AG comments the transaction as follows: "On the basis of the manufacturing license according to §13 AMG (German drug laws) and the ISO-certification 13485 HAEMATO AG has an ideal platform for the development and approval of drugs and medical products. Through this platform we can effectively support the long-term strategy of M1 Kliniken AG in the area of private label developments. At the same time, through M1-Aesthetics we gain access to a business segment that opens up significant earnings potential for our company".

M1 Aesthetics GmbH was valued on the basis of an IDW-S1 expert opinion with an enterprise value of a good € 58 million. The new HAEMATO shares were issued at a reference price of €23.55 per share, which corresponds to the volume-weighted average price of HAEMATO AG in the Xetra trading system in the period from 27.11.2020 to 9.12.2020.

In 2019 M1 Aesthetics GmbH reported sales of about 51 million Euro and an EBIT of almost 7 million Euro. For 2020, M1 Aesthetics GmbH is expecting sales of a good EUR 30 million and an EBIT of approximately EUR 4 million - also due to corona effects, among other things. A further increase in earnings is expected in the coming years.

As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development.


HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing mar-kets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 2,286,715
Listed class of shares: bearer ordinary shares
ISIN: DE000A289VV1
Stock exchange code: HAEK

HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70

15.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Lilienthalstraße 5c
12529 Schönefeld
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
ISIN: DE000A289VV1
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1155330

End of News DGAP News Service

Editor Details

Last Updated: 15-Dec-2020